Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa

Table 3 Prevalence of CYP2D64 and CYP2D617 alleles and inferred phenotypes amongst study participants

CYP2D6 alleles	Enzyme activity	Heterozygote (wt/mt)	Homozygote (mt/mt)	Allele frequency	Activity score	Inferred phenotype
CYP2D6*4	Non-functional	12	2	0.0323	0	PM
CYP2D6*17	Reduced	67	15	0.1956	0.5–1	IM

The genotypes were determined by PCR–RFLP. Genotypes: wildtype/mutant (wt/mt) and mutant/mutant (mt/mt). All genotyping experiments were performed in duplicate in two independent experiments. Inferred phenotypes: intermediate metaboliser (IM) and poor metaboliser (PM)

ISSN: 1475-2875